Pe­ter Marks dish­es on Covid-19 vac­cine de­vel­op­ment at BIO

Pe­ter Marks, di­rec­tor of the FDA’s Cen­ter for Bi­o­log­ics Eval­u­a­tion and Re­search (CBER) told a pan­el at BIO Dig­i­tal he thinks glob­al reg­u­la­tors will be aligned on the clin­i­cal end­points and de­sign fea­tures of Phase II and III clin­i­cal tri­als for vac­cines to pre­vent Covid-19.

Marks al­so em­pha­sized that FDA is work­ing close­ly with its col­leagues around the world to ex­pe­dite the de­vel­op­ment and avail­abil­i­ty of safe and ef­fec­tive vac­cines to ad­dress the pan­dem­ic.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER